Terms: = Endocrine gland cancer AND HER1, YOR227W AND Treatment
17 results:
1. NRF2 Regulates her1 Signaling Pathway to Modulate the Sensitivity of Ovarian cancer Cells to Lapatinib and Erlotinib.
Kankia IH; Khalil HS; Langdon SP; Moult PR; Bown JL; Deeni YY
Oxid Med Cell Longev; 2017; 2017():1864578. PubMed ID: 29410730
[TBL] [Abstract] [Full Text] [Related]
2. The prognostic significance of human epidermal growth factor receptor family protein expression in operable pancreatic cancer : her1-4 protein expression and prognosis in pancreatic cancer.
Li Q; Zhang L; Li X; Yan H; Yang L; Li Y; Li T; Wang J; Cao B
BMC Cancer; 2016 Nov; 16(1):910. PubMed ID: 27871278
[TBL] [Abstract] [Full Text] [Related]
3. An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
Wang Z; Fu S
Expert Opin Investig Drugs; 2016; 25(1):15-30. PubMed ID: 26560712
[TBL] [Abstract] [Full Text] [Related]
4. Dual targeting of her1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial.
Assenat E; Azria D; Mollevi C; Guimbaud R; Tubiana-Mathieu N; Smith D; Delord JP; Samalin E; Portales F; Larbouret C; Robert B; Bibeau F; Bleuse JP; Crapez E; Ychou M; Pèlegrin A
Oncotarget; 2015 May; 6(14):12796-808. PubMed ID: 25918250
[TBL] [Abstract] [Full Text] [Related]
5. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.
Pettazzoni P; Viale A; Shah P; Carugo A; Ying H; Wang H; Genovese G; Seth S; Minelli R; Green T; Huang-Hobbs E; Corti D; Sanchez N; Nezi L; Marchesini M; Kapoor A; Yao W; Francesco ME; Petrocchi A; Deem AK; Scott K; Colla S; Mills GB; Fleming JB; Heffernan TP; Jones P; Toniatti C; DePinho RA; Draetta GF
Cancer Res; 2015 Mar; 75(6):1091-101. PubMed ID: 25736685
[TBL] [Abstract] [Full Text] [Related]
6. Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.
Luedke E; Jaime-Ramirez AC; Bhave N; Carson WE
J Immunother; 2012 Jun; 35(5):367-73. PubMed ID: 22576341
[TBL] [Abstract] [Full Text] [Related]
7. Vandetanib: first global approval.
Commander H; Whiteside G; Perry C
Drugs; 2011 Jul; 71(10):1355-65. PubMed ID: 21770481
[TBL] [Abstract] [Full Text] [Related]
8. High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Hayashi A; Souzaki R; Tajiri T; Onimaru M; Manabe T; Ohtsuka T; Tanaka M
Int J Oncol; 2011 Mar; 38(3):629-41. PubMed ID: 21243324
[TBL] [Abstract] [Full Text] [Related]
9. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
Haluska P; Carboni JM; TenEyck C; Attar RM; Hou X; Yu C; Sagar M; Wong TW; Gottardis MM; Erlichman C
Mol Cancer Ther; 2008 Sep; 7(9):2589-98. PubMed ID: 18765823
[TBL] [Abstract] [Full Text] [Related]
10. Protein levels and gene expressions of the epidermal growth factor receptors, her1, HER2, HER3 and HER4 in benign and malignant ovarian tumors.
Steffensen KD; Waldstrøm M; Andersen RF; Olsen DA; Jeppesen U; Knudsen HJ; Brandslund I; Jakobsen A
Int J Oncol; 2008 Jul; 33(1):195-204. PubMed ID: 18575766
[TBL] [Abstract] [Full Text] [Related]
11. Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions.
Wiseman SM; Griffith OL; Melck A; Masoudi H; Gown A; Nabi IR; Jones SJ
Am J Surg; 2008 May; 195(5):667-73; discussion 673. PubMed ID: 18424286
[TBL] [Abstract] [Full Text] [Related]
12. Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.
Senderowicz AM; Johnson JR; Sridhara R; Zimmerman P; Justice R; Pazdur R
Oncology (Williston Park); 2007 Dec; 21(14):1696-706; discussion 1706-9, 1712, 1715. PubMed ID: 18247017
[TBL] [Abstract] [Full Text] [Related]
13. Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells.
Kurebayashi J; Okubo S; Yamamoto Y; Ikeda M; Tanaka K; Otsuki T; Sonoo H
Cancer Chemother Pharmacol; 2006 Oct; 58(4):460-70. PubMed ID: 16435154
[TBL] [Abstract] [Full Text] [Related]
14. Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study.
Leibl S; Bodo K; Gogg-Kammerer M; Hrzenjak A; Petru E; Winter R; Denk H; Moinfar F
Gynecol Oncol; 2006 Apr; 101(1):18-23. PubMed ID: 16330088
[TBL] [Abstract] [Full Text] [Related]
15. Emerging drugs for ovarian cancer.
Kelland LR
Expert Opin Emerg Drugs; 2005 May; 10(2):413-24. PubMed ID: 15934876
[TBL] [Abstract] [Full Text] [Related]
16. Monoclonal antibody therapy of ovarian cancer.
Nicodemus CF; Berek JS
Expert Rev Anticancer Ther; 2005 Feb; 5(1):87-96. PubMed ID: 15757441
[TBL] [Abstract] [Full Text] [Related]
17. Can rash associated with her1/EGFR inhibition be used as a marker of treatment outcome?
Pérez-Soler R
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):23-8. PubMed ID: 14682120
[TBL] [Abstract] [Full Text] [Related]